Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06705816 · ClinicalTrials.gov registry record

Cognitive Function in Rett Syndrome During Trofinetide Treatment

A clinical trial of Rett Syndrome, sponsored by University of Minnesota.

Recruiting
Registry status
20
Enrollment target
1
Study location

NCT06705816: Recruiting study of Rett Syndrome, sponsored by University of Minnesota.

NCT06705816 is a study of Rett Syndrome that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 20 participants, below the 525-participant average among 18 other Rett Syndrome trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06705816, a study of Rett Syndrome, is actively recruiting participants, sponsored by University of Minnesota.

RECRUITING
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

Assessing cognitive functions among individuals with severe intellectual and developmental disabilities (IDD), including RTT, is often challenging due to floor effects of many standardized assessment batteries in this population. In addition, deficits in motor function and verbal ability may obscure certain abilities in this population when using standard IQ measures. Remote eye-tracking tasks have been proposed as an alternative approach for assessing cognitive functions among individuals with severe IDD, because eye-tracking tasks can be designed to minimize the influence of gross motor and receptive language deficits on performance. Although several types of eye-tracking tasks have been evaluated in RTT, most have been implemented only at a single time-point. As a result, it is unclear whether these measures are stable over time, or sensitive to developmental changes or alterations to health status that occur in RTT (e.g., developmental regression, development of seizures, change in medication, etc.). With the recent FDA approval of trofinetide for the treatment of RTT, we have a novel opportunity to test the sensitivity of eye-tracking and other psychophysiological measures to treatment changes. Anecdotally, parents and clinicians have reported improvements in attention and alertness during trofinetide treatment, but currently available outcome measures do not capture these types of effects. Therefore, we propose to conduct a pilot trial of changes in measures of attention, oculomotor function, learning, and autonomic function, all collected using non-invasive measures, during trofinetide treatment. This is an observational within-subject design with a 4-week post-treatment assessment compared to two pre-treatment assessments. Additional optional follow-up assessments will be performed with families who are interested and returning for standard-of-care visits to Gillette or who are willing to travel for a research-only visit.

Primary Outcome

change in saccade latencies during the 'statistical learning' paradigm

Conditions Studied

Interventions

  • OTHER None interventional

Study Locations (1)

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-12-01
Est. Completion 2026-06
University of Minnesota

966 total trials

What NCT06705816 shows while recruiting

NCT06705816 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 525-participant average among 18 other Rett Syndrome trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Rett Syndrome appearing as the primary indexed condition, and to 1 intervention - of which None interventional is the first listed.

NCT06705816 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT06705816 about?

NCT06705816 is a clinical study titled "Cognitive Function in Rett Syndrome During Trofinetide Treatment". Assessing cognitive functions among individuals with severe intellectual and developmental disabilities (IDD), including RTT, is often challenging due to floor effects of many standardized assessment batteries in this population. In addition, deficits in motor function and verbal ability may obscure...

What is the current status of trial NCT06705816?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2024-12-01. Estimated completion is 2026-06.

What conditions does trial NCT06705816 study?

This clinical trial studies the following conditions: Rett Syndrome.

What interventions are being tested in trial NCT06705816?

The interventions under investigation include: None interventional (OTHER).

Who is sponsoring clinical trial NCT06705816?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06705816 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rett Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06705816's enrollment target sits among peer trials

20 14th of 18 higher than 5 of 18 other Rett Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rett Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06705816, the US trial registry maintained by the National Library of Medicine. NCT06705816 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.